Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.

Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page revision label changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedThe notice about a lapse in government funding warning that information may not be up to date was removed from the page. Core study details, contacts, and eligibility criteria remain unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedThe two screenshots depict the same study detail page with only minor visual and layout differences; no substantive updates to the study data (eligibility, enrollment, or outcomes) were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check71 days agoChange DetectedUpdated operating-status notice and version 3.2.0; removed version 3.1.0.SummaryDifference4%

- Check78 days agoChange DetectedUpdate to revision from v3.0.2 to v3.1.0 and addition of contact details for Sabine Zoechbauer-Mueller (sabine.zoechbauer-mueller@meduniwien.ac.at) with a phone-like number; effectively a version upgrade plus new contact information.SummaryDifference0.1%

- Check92 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, and the Back to Top element was removed.SummaryDifference0.2%

Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.